Sanofi emerged from a challenging US FDA advisory committee review of Dengvaxia with strongly positive votes on two of four questions posed to the panel, thanks in large part to the agency’s own apparent enthusiasm for the controversial dengue vaccine.
Throughout the March 7 meeting of the Vaccines and Related Biological Products Advisory Committee, staff in the Center for Biologics...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?